Table 1. TNBC patient characteristics, N = 10 patients.
| Patient ID | Tumor location | Histology type | Age | Stage | Neo(adjuvant) chemotherapy | Radiation | RFS month | OS month |
|---|---|---|---|---|---|---|---|---|
| COH-1.1 | Breast primary | IDC | 64 | IIA | AC-T | Yes | 34 | 89 |
| COH-1.2 | Lung met | |||||||
| COH-2.1 | Breast primary | IDC | 51 | IIIA | AC | Declined | 17 | 60 |
| COH-2.2 | LN met | |||||||
| COH-2.3 | Bone met | |||||||
| COH-3.1 | Breast 2nd primary | IDC | 41 | IIIA | AC | Declined | 39 | 92 |
| COH-3.2 | LN met | |||||||
| COH-4.1 | LN primary | IDC | 44 | IIIB | Carbo/Taxol | Yes | 10 | 28 |
| COH-4.2 | Liver met | |||||||
| COH-5.1 | Breast primary | IDC | 39 | IIIC | AC | No | 2 | 9 |
| COH-5.2 | Skin met | |||||||
| COH-6.1 | Brain met | IDC | 50 | IIA | TAC | Declined | 31 | 67 |
| COH-6.2 | Soft tissue met | |||||||
| COH-7.1 | Breast primary | IDC | 58 | IA | Declined | Declined | 26 | 46 |
| COH-7.2 | LN met | |||||||
| COH-8.1 | Endometrium met | IDC | 38 | IV | N.A. | No | 11 | 58 |
| COH-8.2 | LN met | |||||||
| COH-9.1 | Breast primary | ILC | 45 | IIB | AC-T | Yes | 8 | 23 |
| COH-9.2 | Breast met | |||||||
| COH-10.1 | Breast primary | Metaplastic | 51 | IIB | AC-T | Yes | 16 | 58 |
| COH-10.2 | Lung met | |||||||
| COH-10.3 | Brain met |
LN, lymph node; RFS, relapse-free survival; OS, overall survival; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; AC, doxorubicin, cyclophosphamide; AC-T, doxorubicin, cyclophosphamide followed by docetaxel; Carbo/Taxol, carboplatin and paclitaxel.